ÂÜÀòÂÒÂ×

Ingrid Braenne has an extensive work experience in the field of scientific research and data analysis. Ingrid started their career as a PHD student at the Graduate School for Computing in Medicine and Life Sciences, University of Lübeck, where they focused on using machine learning algorithms to identify disease-specific patterns in genome-wide association data. Ingrid completed their PHD with honors and also supervised bachelor and master students while teaching bioinformatics and neuroinformatics.

After completing their PHD, Braenne worked as a Postdoctoral Researcher at Universitätsklinikum Schleswig-Holstein, Medizinische Klinik II, where they established a next-generation sequencing analysis pipeline and identified disease-causing variants in families and case-only studies, with a focus on coronary artery disease.

Following their postdoctoral position, Braenne became a Group Leader at the University of Lübeck, where they continued their research on coronary artery disease. Ingrid established new methods and pipelines to identify common and rare risk variants in genome-wide association studies, conducted SNP-SNP interaction studies, and performed classification on GWAS and NGS data.

Braenne then joined the University of Virginia as a Senior Scientist, where they focused on gene co-expression network analysis, establishing pipelines to analyze longitudinal transcriptomics data, and identifying biomarkers to predict the development of disease, with a main focus on type 1 diabetes.

Ingrid later worked as a Team Manager Data Science at Definiens, The Tissue Phenomics Company, where they oversaw a team and contributed to projects related to data science.

Most recently, Braenne joined AstraZeneca as an Associate Principal Scientist, and later became an Associate Director. Ingrid'sroles at AstraZeneca involved contributing to drug discovery and development, with a focus on cardiovascular diseases.

In 2023, Braenne is set to join Boehringer Ingelheim as a Principal Scientist.

Overall, Ingrid Braenne's work experience showcases their expertise in scientific research, data analysis, and leadership roles in the pharmaceutical and academia sectors.

Ingrid Braenne completed their education as follows: they earned their Bachelor of Science (B.Sc.) in Molecular Biotechnology from Universität zu Lübeck in 2004, followed by a Master of Science (M.Sc.) in Molecular Life Science from the same institution in 2006. Ingrid also participated in a study abroad program at the University of Oslo (UiO) in 2006, specifically at the Institute for Medical Biochemistry. In 2011, Ingrid completed their PhD in Bioinformatics from Universität zu Lübeck. Prior to their higher education, they received secondary education at Fagerlia Videregående Skole Ålesund.